46 results about "Viral immunization" patented technology

The invention discloses sgRNAs of a specific targeting grass carp RIOK3 gene and a construction method and application of an RIOK3 gene knockout cell line, and belongs to the technical field of gene engineering. The invention provides sgRNAs of a specific targeting grass carp RIOK3 gene and a sequence of a primer group, and also provides a method for constructing a large-fragment knockout cell line of the RIOK3 gene in combination with the sgRNAs, and application of the gene knockout cell line in research on an anti-virus infection mechanism of grass carp. The invention discloses the construction of the grass carp gene in-vitro research model by knocking out the antiviral negative regulatory factor RIOK3 of the fish cells by using the CRISPR-Cas9 technology for the first time, provides an in-vitro research material and a new way for the analysis of an antiviral immune regulation molecular mechanism of the grass carp, and particularly has important guiding significance for the research of resisting grass carp reovirus infection.

Disclosed herein are compositions and methods for eliciting an immune response to an antigen. More particularly, disclosed herein are compositions suitable for eliciting immune responses to a plurality of viruses, including Epstein-Ban vims (EBV), cytomegalovirus (CMV), polyoma BK vims (BKV), polyoma JC vims (JCV), and adenovims (Adv), and methods of using such compositions for treatment and prophylaxis.

The invention, in some aspects, relates to compositions comprising modified viral nucleocapsid (N) proteins and their encoding polynucleotides and methods of using such compositions and preparations to increase viral N protein dimerization and / or increase antigenicity of viral immunization preparations.

The invention relates to a cherry valley duck PLV virus vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus immunity. The vaccine is prepared by taking a Parry's Lagon virus (PLV) virus strain PLV-20155 as an immunogen, the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46296. The invention further discloses a preparation method of the vaccine. The vaccine is a PLV-20155 virus inactivated vaccine, and the preparation method of the vaccine comprises the following steps: inoculating the PLV-20155 virus into an SPF chick embryo for propagation, harvesting a virus liquid, inactivating with formaldehyde, verifying safety, emulsifying with white oil to prepare the vaccine and the like. In addition, the vaccine disclosed by the invention can be used for effectively preventing diseases such as laying rate reduction, follicle necrosis and fallopian tube atrophy of the cherry valley ducks caused by the PLV-20155 virus, and the economic benefit of breeding is remarkably improved.

The invention belongs to the technical field of virus immunodetection, and relates to detection of swine transmissible gastroenteritis virus, in particular to a Mab 12H6 antibody, a colloidal gold test strip and application. According to the invention, TGEV N protein is used as an antigen of a detection line, Mab 12H6 is used as a detection antibody combined with colloidal gold, condition optimization is carried out through different methods, the specificity and sensitivity of the methods are evaluated, and a detection method for detecting the antigen based on an N protein TGEV colloidal gold competition method is established. The established TGEV colloidal gold test strip has the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of TGEV in a porcine diarrhea sample clinically.

The present invention is in the field of viral immunotherapy. The invention provides 1) an efficient recombinant poxvirus expressing a toxic conditional gene product that affects the viability of the recombinant poxvirus itself if left unregulated, or 2) a recombinant poxvirus expressing a conditional gene product with an improved safety profile, a method of producing them, a composition comprising them and therapeutic uses related thereto.

The invention belongs to the technical field of virus immunodetection, and relates to a Mab 6B7 antibody, a colloidal gold test strip and application. According to the invention, PDCoV N protein is used as an antigen of a detection line, Mab 6B7 is used as a detection antibody combined with colloidal gold, condition optimization is carried out through different methods, the specificity and sensitivity of the methods are evaluated, and a detection method for detecting the antigen based on an N protein PDCoV colloidal gold competition method is established. The established PDCoV colloidal gold test strip has the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of PDCoV in a porcine diarrhea sample clinically.

Embodiments herein concern compositions, methods, and uses for inducing an immune response to all four dengue virus serotypes in a child or young adult from about 1 year to about 20 years of age. Some embodiments concern compositions that can include, but are not limited to, dengue virus chimeras that, either alone or in combination with other constructs, can be used in a vaccine composition against all four dengue virus serotypes. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) virus and / or dengue-4 (DEN-4) virus, at various concentrations or ratios in order to improve protection from infection in children and young adults. In certain embodiments, viruses of the formulations are limited to dengue virus serotypes. Other embodiments concern methods of administering immunogenic compositions against dengue virus that can include chimeric dengue constructs and live, attenuated dengue viruses using single, dual or other regimens.

The application discloses a novel goose parvovirus VP1 protein truncated body gene, a recombinant duck plague virus and application. The novel goose parvovirus VP1 protein truncated body gene has a nucleotide sequence shown as SEQ ID No. 1. The recombinant duck plague virus has the novel goose parvovirus VP1 protein truncated body gene inserted into the genome of the recombinant duck plague virus. The application obtains a novel goose parvovirus VP1 protein truncated body gene, inserts the truncated body into the genome of the recombinant duck plague virus, and obtains the recombinant duck plague virus, and the rsVP1-Cre immune group shortens the NGPV discharge in the duck body, and the duck body immune rsVP1-Cre is helpful to the NGPV discharge. It is shown that the recombinant duck plague virus with the VP1 protein truncated body gene inserted can be used for preparation of a novel goose parvovirus-duck plague virus double live vector vaccine.

The invention discloses siRNA for inhibiting expression of a large yellow croaker SOCS1 gene and application of the siRNA. The target gene cDNA sequence of the siRNA is as shown in SEQ ID NO.1. By transfecting siRNA (siSOCS1-237) into a large yellow croaker head kidney cell strain, the expression of SOCS1 in the cell can be specifically inhibited, and the expression of an anti-virus immune gene of the large yellow croaker is promoted, so that the anti-virus immune response of the large yellow croaker is enhanced. The invention proves that the siRNA is expected to be developed into a novel pseudosciaena crocea antiviral drug, and lays a foundation for preventing and controlling marine fish virus diseases.

This invention provides novel compositions and methods for effectively stimulating antiviral immunity. [Solution] A composition comprising (a) a vector comprising a plasmid encoding at least one viral antigen; and (b) a vector comprising a CD1d recognition antigen; and (c) at least one pharmaceutically acceptable carrier, wherein at least one of vectors (a) and (b) is an intact bacterial minicell or a dead bacterial cell.

According to the application, a duck reovirus immune mouse and a conventional monoclonal antibody preparation method are adopted to obtain the anti-duck reovirus muNS protein specific monoclonal antibody, the preservation number of a hybridoma cell is CGMCC No.46129, the antibody secreted by the hybridoma cell is 3C3, a method for blocking ELISA detection is constructed by the antibody, clinical serum is compared and detected, and the monoclonal antibody can be used for detecting the duck reovirus muNS protein. Compared with a Western Blot method and an indirect immunofluorescence method, the method has the same result, and the method is high in detection specificity, large in flux, low in cost and visual in result, so that the requirement of current basic duck reovirus monitoring is met.

The present invention is in the field of viral immunotherapy. The invention provides new pseudocowpox (PCPV) viruses, in particular recombinant PCPV, composition thereof as well as their therapeutic use for preventing or treating diseases, and, notably, proliferative diseases like cancers and restenosis and infectious diseases such as chronic ones. The present invention also provides methods for generating and amplifying such a PCPV and a method for eliciting or stimulating and / or re-orienting an immune response using such a PCPV. More specifically, the invention provides an alternative to the existing poxvirus vectors such as MVA (Modified Virus Ankara) and may be largely used for the therapeutic vaccination.

To provide EBV ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.SOLUTION: Provided herein, in some embodiments, are Epstein-Barr virus (EBV) ribonucleic acid (RNA) (e.g., mRNA) vaccines (e.g., combination vaccines) that elicit potent neutralizing antibodies and robust T cell responses, inhibit the production of viral immunomodulatory factors, and / or prevent viral latency.SELECTED DRAWING: None

The application discloses a PEDV S protein N-glycosylation site mutant virus and application thereof. The application immunizes mice with the mutant virus to detect the influence of N-glycosylation of S protein on virus immunogenicity, and it is found that the recombinant PEDV virus strain with single-point mutation of N216, N324 and N1261 glycosylation sites of S protein can activate mice to produce a higher level of neutralizing antibody, and can be increased by 3.2 times (N216A), 6.7 times (N324A) and 3.2 times (N1261A). The recombinant PEDV virus strains with mutation of the three sites can be used as potential PEDV inactivated vaccine candidate strains.

The present disclosure relates to an immune composition comprising or encoding a human respiratory syncytial virus antigen, selected from the group consisting of a nucleic acid immune composition, a polypeptide immune composition or a viral immune composition.

The invention belongs to the technical field of virus immunity, and particularly relates to a hantavirus nucleocapsid protein pan-MHC-I epitope peptide, a vaccine and application. The pan-MHC-I epitope peptide of the hantavirus nucleocapsid protein is at least one of amino acid sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 4. The epitope peptide is used for preparing the vaccine, the immune effect of the vaccine is verified, and meanwhile, the epitope peptide is used for evaluating the effectiveness of the vaccine in the prior art. The invention clarifies the immunological characteristics of hantavirus NP antigens and the application potential of the hantavirus nucleocapsid protein pan-MHC-I epitope peptides in virus infection, disease progression and prevention. The hantavirus nucleocapsid protein pan-MHC-I epitope peptide and the corresponding vaccine are developed by using the MHC-I epitope, and CD8 + T cell response can be remarkably enhanced and activated, so that the defect of singly using the MHC-II epitope is overcome.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus (CSFV) recombinant E2 protein and application, and relates to the technical field of biology.The TK / gE double gene deletion PRV attenuated strain is used as a virus carrier, an exogenous CSFV E2 gene with a transmembrane region removed is inserted after a PRV gC signal peptide sequence, and a recombinant virus rPRV-delTK / gE-gC-E2 for expressing the gC N terminal and fusing with the PRV gC is constructed; Western blotting analysis and indirect immunofluorescence detection prove that the gC-E2 protein is successfully expressed.The recombinant virus immunized mice can produce specific antibodies against E2; after immunizing piglets, the piglets can produce an antibody level equivalent to that of a classical CSFV attenuated vaccine strain C strain.The rPRV-delTK / gE-gC-E2 obtained in the research is a promising bivalent live vaccine candidate strain.

The application provides a kind of biotinylated ferritin complex and its preparation method and application, belong to virus immune detection technical field.The biotinylated ferritin complex of the application inserts biotin receptor peptide (BAP) into Loop region, is obtained by co-transforming escherichia coli with recombinant plasmid pET28a-BAP-HFn and pETDuet-BirA (Loop-Biotin-HFn).It is assembled with HRP labeled streptavidin (SA-HRP) according to 1:26 molar ratio, and Loop-BNC complex is obtained.The Loop-BNC can be used as signal amplification probe, and is used for the detection of SARS-CoV-2 N protein by using sandwich ELISA method, and the detection sensitivity is lower than 0.0001 ng / mL, the detection effect is optimal in 0.0001-0.1 ng / mL, with the advantages of high signal-to-noise ratio and strong specificity.The application retains the high loading capacity and structural stability of ferritin, realizes the early and accurate detection of SARS-CoV-2 N protein, and provides efficient and reliable technical support and probe material for novel coronavirus detection.

The invention belongs to the technical field of virus immunodetection, and relates to a colloidal carbon test strip for detecting swine transmissible gastroenteritis virus based on a nano antibody and application of the colloidal carbon test strip. According to the TGEV colloidal carbon detection method established by the invention, Mab 12H6 is screened as a carbon labeled antibody, the concentration of N protein coated by a T line is 0.7 mg / mL, the use amount of a probe is 6 [mu] L, and the detection time is 10 min, a virus solution (5 * 10 < 4 > TCID50) with the antigen content of 1 / 256 can be sensitively detected, the specificity is good, and the detection coincidence rate of clinical test products is 95.2%. The test strip has the advantages of high specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of TGEV in a porcine diarrhea sample clinically.

The invention relates to the technical field of fish genetic breeding, in particular to a gene FTR100 related to a crucian carp interferon antiviral immune response and application of the gene FTR100. Gene related to the antiviral immune response of the crucian carp interferon is FTR100, the invention further discloses three specific knockout targets of the FTR100 gene, the crucian carp FTR100 gene is specifically knocked out by utilizing a CRISPR / Cas9 gene editing technology, and a mutant genotype individual with three alleles terminated in advance, namely the crucian carp with high resistance to the crucian carp herpesvirus, is obtained. According to the invention, the function of the FTR100 in the prussian carp is verified for the first time, a new germplasm with improved capability of resisting the herpesvirus of the prussian carp is rapidly obtained by knocking out a single gene of the FTR100, and the method has important industrial value.

The invention belongs to the technical field of biological medicines, and particularly relates to a biological cell regulating solution, a preparation method of the regulating solution and application of the regulating solution in the aspects of virus resistance, inflammation resistance and immune regulation. The method has the advantages that by accurately controlling the dilution concentration of the electromagnetic base liquid and key parameters such as the reduction potential and the pH value of the diluent, it is ensured that hydration electrons in the diluent can form a stable quantum state structure, and a foundation is laid for the subsequent biological regulation function. The biological cell regulation liquid is applied to anti-inflammatory, anti-virus and immune regulation, the function that one liquid has multiple purposes is achieved, overlapped medication is not needed, and the medicine has the advantages of being efficient in virus resistance (the virus inactivation rate exceeds 95%), high in selectivity (not affecting normal cells), rapid in effect, lasting and stable in regulation effect, free of excessive immune reaction risk and the like; in addition, the functions of various immune cells can be synchronously enhanced in the aspect of immune regulation, and comprehensive immune regulation is truly realized. In the anti-inflammatory aspect, accurate anti-inflammation can be achieved, the inflammatory factor level is remarkably reduced, the normal physiological function is not affected, the biocompatibility is good in use, and no accumulative side effect exists.

The invention discloses a recombinant pseudorabies virus strain for expressing hog cholera virus recombinant E2 protein and application, and relates to the technical field of biology. According to the research, a TK / gE double-gene deleted PRV attenuated strain is used as a virus vector, and after an exogenous CSFV E2 gene without a transmembrane region is inserted into a PRV gG signal peptide sequence, a recombinant virus rPRV-delTK / gE-gG-E2 which is positioned at a gG N end and is subjected to fusion expression with PRV gG is constructed; western blotting analysis and indirect immunofluorescence detection prove that the gG-E2 protein is successfully expressed. A recombinant virus immunized mouse can generate a specific antibody aiming at E2; after piglets are immunized, an antibody level equivalent to that of a classical CSFV attenuated vaccine strain C strain can be generated. The rPRV-delTK / gE-gG-E2 obtained by the research is a bigeminy live vaccine candidate strain with an extremely promising prospect.

The invention belongs to the technical field of virus immunodetection, and relates to a colloidal carbon test strip based on a nano antibody and application of the colloidal carbon test strip in detection of porcine deltacoronavirus. According to the invention, PDCoV N protein is used as an antigen of a detection line, Mab 6B7 is used as a detection antibody combined with colloidal carbon, condition optimization is carried out through different methods, the specificity and sensitivity of the methods are evaluated, and a detection method for detecting the antigen based on the N protein PDCoV colloidal carbon competition method is established. The established PDCoV colloidal carbon detection test strip has the advantages of high specificity, high sensitivity, simplicity and convenience in operation, low production cost and the like, and can be applied to rapid detection of PDCoV in a porcine diarrhea sample clinically.

The invention belongs to the technical field of medicines, and discloses application of baicalein in preparation of related medicines for treating human coronavirus 229E infected pneumonia. Specifically, the invention discloses application of baicalein in preparation of medicines playing a protective role in prevention and / or treatment of respiratory dysfunction, lung injury, inflammatory response, virus infection and immune disorder caused by human coronavirus 229E infected pneumonia. Pharmacological experiments prove that baicalein can improve the respiratory function in human coronavirus 229E infected pneumonia, exert anti-inflammatory, anti-virus and immunoregulation effects, and can improve pulmonary edema, thereby achieving the purpose of treatment.

The invention belongs to the technical field of medicines, and discloses application of a Dayuan drink extract in related medicines for treating human coronavirus 229E infected pneumonia. Specifically, the invention discloses application of a Dayuan drink extract in preparation of drugs for protecting respiratory dysfunction, lung injury, inflammatory response, virus infection and immune disorder caused by human coronavirus 229E infected pneumonia. Pharmacological experiments prove that the Dayuan drink extract can improve the respiratory function in human coronavirus 229E infected pneumonia, exert anti-inflammatory, antiviral and immunoregulation effects, and can improve pulmonary edema, thereby achieving the purpose of treatment.

The invention discloses application of long-chain non-coding RNA (LncRNA) XR002626937.1 in regulation and control of replication of canine coronavirus (CCoV), and belongs to the technical field of biological medicine. The nucleotide sequence of the LncRNA XR002626937.1 is as shown in SEQ ID No.1, is mainly positioned in a cell nucleus, is remarkably up-regulated in time and dose dependence after MDCK cells are infected by CCoV, and is positively correlated with virus load. Functional experiments prove that overexpression of the LncRNA can significantly promote CCoV replication, and knock-down of the expression of the LncRNA can effectively inhibit virus proliferation; the action mechanism comprises the steps of inhibiting activation of a p53 signal channel and downstream target genes p21 and Bax, repressing apoptosis of infected cells, antagonizing expression of natural immune factors such as RIG-I, MAVS, ISG15 and the like, promoting virus immune escape, and being capable of serving as competitive endogenous RNA to adsorb miR-10926-z to regulate and control the downstream signal channel. The key function of the LncRNA XR002626937.1 in CCoV infection is defined for the first time, a new target spot and a theoretical basis are provided for developing the anti-CCoV medicine targeting the LncRNA, and the application prospect is wide.

The present invention provides novel nanoparticle presented vaccine compositions that are stabilized with a locking domain. Various immunogens can be employed in the preparation of the vaccine compositions, including viral immunogens such as HIV-1 and Ebola viral immunogens, and non-viral immunogens such as immunogens derived from bacteria, parasites and mammalian species. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating viral infections.

The invention discloses application of a transcription factor NbMYB330 in tobacco antiviral immunity, and belongs to the technical field of biology. The transcription factor NbMYB330 disclosed by the invention is researched and found for the first time that the transcription factor NbMYB330 can regulate and control the accumulation of hydrogen peroxide (H2O2) in a tobacco plant and regulate and control the resistance of tobacco to a potyvirus virus; through overexpression of the NbMYB330 gene, infection of potyvirus viruses can be inhibited, resistance of plants to the potyvirus viruses is improved, obtaining of disease-resistant plants is facilitated, and the NbMYB330 gene has important application value.

Present invention provides a method of producing clarified virus pool of virus to obtain a lyophilized / freeze-dried live attenuated virus immunogenic composition / formulation comprising atleast one or more than one antigens / immunogens. Present invention provides a method of producing a clarified virus pool of viruses such as measles, mumps, rubella. It provides the improved large scale affordable / safe manufacturing processes (encompassing cultivation, purification & formulation stages) that utilize minimum animal origin components, provide high virus yield, ensure virus integrity / stability preservation across manufacturing & storage.